 Marker Therapeutics, Inc. Nasdaq:MRKR, a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced today that the United States Adopted Names USAN Council has approved zelenoleucel as the nonproprietary generic name for MT-401, a multi-tumor-associated antigen MultiTAA-specific T cell product candidate for the treatment of patients with acute myeloid leukemia AML following allogeneic stem cell transplant in both adjuvant and active disease settings. 